GlassScriptPhysician profile
Mark J Saxon
NPI 1255389326
$21,489.73
in general payments reported to CMS, 2019-2025
40 companies · $2,983 in 2025
The $2,983 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,995 · 2020: $1,068 · 2021: $1,729 · 2022: $2,546 · 2023: $3,066 · 2024: $3,102 · 2025: $2,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,928 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,927.83 |
| Education | $222.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $3,320.48 | 2019-2025 | Trintellix |
| Allergan, INC. | $2,836.24 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $1,813.20 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,694.37 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $1,693.13 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,620.54 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $1,616.81 | 2019-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $1,141.35 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $837.74 | 2020-2025 | Caplyta |
| Lundbeck LLC | $648.90 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $589.73 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $436.93 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $436.91 | 2019-2022 | |
| Corium, LLC | $360.97 | 2022-2025 | Azstarys, Azstarys |
| E.R. Squibb & Sons, L.L.C. | $319.94 | 2024-2025 | Cobenfy |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Saxon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.